Curaleaf Holdings (CURLF) Non-Current Assets (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Assets of $2.4 billion for Q4 2025, down 4.72% year-over-year from $2.5 billion in Q4 2024, and down 4.72% quarter-over-quarter from $2.5 billion in Q4 2024.
Curaleaf Holdings (CURLF) Non-Current Assets (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Non-Current Assets history runs 7 years deep, the most recent figure standing at $2.4 billion for Q4 2025.
- In Q4 2025, Non-Current Assets fell 4.72% year-over-year to $2.4 billion; the TTM figure through Dec 2025 stood at $10.5 billion (up 46.22% YoY), while the FY2025 annual figure was $2.4 billion, down 4.72% from the prior year.
- Non-Current Assets for Q4 2025 stood at $2.4 billion, down from $2.5 billion in the prior quarter.
- The five-year high for Non-Current Assets was $2.8 billion in Q2 2023, with the low at -$974.4 billion in Q1 2022.
- The 5-year median for Non-Current Assets is $2.0 billion (2021), against an average of -$63.8 billion.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets slumped 49767.67% in 2022, then jumped 28460.72% in 2024.
- Curaleaf Holdings' Non-Current Assets stood at $10.4 million in 2021, then jumped by 23569.62% to $2.5 billion in 2022, then plunged by 99.64% to $8.8 million in 2023, then surged by 28460.72% to $2.5 billion in 2024, then slipped by 4.72% to $2.4 billion in 2025.
- Business Quant data shows CURLF's Non-Current Assets at $2.4 billion in Q4 2025, $2.5 billion in Q4 2024, and $8.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | 2.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Bn |
| Dec 31, 2025 | 2.40 Bn |
| Dec 31, 2024 | 2.52 Bn |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 8.39 Mn |
| Dec 31, 2023 | 8.81 Mn |
| Sep 30, 2023 | 2.74 Bn |
| Jun 30, 2023 | 2.84 Bn |
| Dec 31, 2022 | 2.46 Bn |
| Sep 30, 2022 | -920.77 Mn |
| Jun 30, 2022 | -933.63 Mn |
| Mar 31, 2022 | -974.43 Bn |
| Dec 31, 2021 | 10.40 Mn |
| Sep 30, 2021 | 2.27 Bn |
| Jun 30, 2021 | 2.35 Bn |
| Mar 31, 2021 | 1.96 Bn |
| Dec 31, 2020 | 1.95 Bn |
| Sep 30, 2020 | 1.98 Bn |
| Dec 31, 2019 | 587.40 Mn |